Type 2 diabetes patients who took saxagliptin did not have a higher risk of heart attack, stroke or cardiovascular death than those who took a placebo pill, a study in the New England Journal of Medicine indicated. Researchers also found patients in the saxagliptin arm attained better glucose control and reduced insulin therapy requirements. However, researchers noted an increased rate of hospitalization for heart failure among saxagliptin-treated patients, which merits further evaluation.

Full Story:
HealthDay News

Related Summaries